
Pramlintide
Pramlintide is a synthetic analog of human amylin, a beta-cell co-secreted peptide with insulin. In research settings it’s used to study postprandial glucose co…
Half-life
~45–60 minutes (SC); pharmacodynamic effects ~2–3 hours
Delivery
Subcutaneous injection immediately prior to major meals (separate site from insulin).
Suggested dosage
Not specified
Usage
Mechanism of action
Benefits (4)
- Reduces postprandial glucose excursions
- Decreases glucagon surge after meals
- Slows gastric emptying
- May reduce appetite and caloric intake
Side effects (5)
- Nausea, vomiting, abdominal discomfort
- Decreased appetite
- Injection-site reactions
- Hypoglycemia when used with insulin (requires mealtime insulin dose reduction)
- Boxed warning: severe insulin-induced hypoglycemia risk, especially within 3 hours post-dose